These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36310836)

  • 1. Clinical Significance of the Highest Regional Bone Scan Index in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Nakai Y; Iemura Y; Miyasaka T; Hori S; Miyake M; Marugami N; Fujimoto K; Tanaka N
    Nucl Med Mol Imaging; 2022 Oct; 56(5):221-227. PubMed ID: 36310836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.
    Poulsen MH; Rasmussen J; Edenbrandt L; Høilund-Carlsen PF; Gerke O; Johansen A; Lund L
    BJU Int; 2016 May; 117(5):748-53. PubMed ID: 25906907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice.
    Reza M; Ohlsson M; Kaboteh R; Anand A; Franck-Lissbrant I; Damber JE; Widmark A; Thellenberg-Karlsson C; Budäus L; Steuber T; Eichenauer T; Wollmer P; Edenbrandt L; Trägårdh E; Bjartell A
    Eur Urol Focus; 2016 Dec; 2(5):540-546. PubMed ID: 28723520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study.
    Reza M; Jones R; Aspegren J; Massard C; Mattila L; Mustonen M; Wollmer P; Trägårdh E; Bondesson E; Edenbrandt L; Fizazi K; Bjartell A
    Eur Urol Focus; 2016 Dec; 2(5):547-552. PubMed ID: 28723521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the Prognosis of Prostate Cancer Bone Metastasis Using the Bone Scan Index and Hot Spots Calculated Using VSBONEⓇ Bone Scan Index from Tc-99m-Hydroxymethylene Diphosphonate Bone Scintigraphy.
    Higashiyama S; Yoshida A; Kawabe J
    Urol Int; 2022; 106(9):963-969. PubMed ID: 35249033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study.
    Zacho HD; Gade M; Mortensen JC; Bertelsen H; Boldsen SK; Barsi T; Petersen LJ
    Urology; 2017 Oct; 108():135-141. PubMed ID: 28760556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide.
    Poteska R; Rahbar K; Semjonow A; Schrader AJ; Boegemann M; Schlack K
    BMC Cancer; 2022 Apr; 22(1):375. PubMed ID: 35395766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Tablazon IL; Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ; Williams SB
    Cancer; 2019 Nov; 125(22):4003-4010. PubMed ID: 31390061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate.
    Miyashita H; Cruz C; Patel V
    Support Care Cancer; 2022 Feb; 30(2):981-984. PubMed ID: 34373957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis.
    Schlack K; Krabbe LM; Rahbar K; Isenberg K; Semjonow A; Schrader AJ; Boegemann M
    Transl Androl Urol; 2021 Oct; 10(10):3986-3999. PubMed ID: 34804841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
    Dennis ER; Jia X; Mezheritskiy IS; Stephenson RD; Schoder H; Fox JJ; Heller G; Scher HI; Larson SM; Morris MJ
    J Clin Oncol; 2012 Feb; 30(5):519-24. PubMed ID: 22231045
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
    J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
    Armstrong AJ; Kaboteh R; Carducci MA; Damber JE; Stadler WM; Hansen M; Edenbrandt L; Forsberg G; Nordle Ö; Pili R; Morris MJ
    Urol Oncol; 2014 Nov; 32(8):1308-16. PubMed ID: 25240761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.
    Anand A; Morris MJ; Larson SM; Minarik D; Josefsson A; Helgstrand JT; Oturai PS; Edenbrandt L; Røder MA; Bjartell A
    EJNMMI Res; 2016 Dec; 6(1):23. PubMed ID: 26960325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone Scan Index predicts skeletal-related events in patients with metastatic breast cancer.
    Idota A; Sawaki M; Yoshimura A; Hattori M; Inaba Y; Oze I; Kikumori T; Kodera Y; Iwata H
    Springerplus; 2016; 5(1):1095. PubMed ID: 27468396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
    Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases.
    Hirano H; Nagata M; Nagaya N; Nakamura S; Ashizawa T; Lu Y; Kawano H; Kitamura K; Sakamoto Y; Fujita K; Isobe H; Tsujimura A; Muto S; Horie S
    Sci Rep; 2023 May; 13(1):8704. PubMed ID: 37248346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial.
    Tong T; Lei H; Guan Y; Yang X; Liao G; Li Y; Jiang D; Pang J
    Front Oncol; 2020; 10():586192. PubMed ID: 33330067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing Therapeutic Response to Radium-223 with an Automated Bone Scan Index among Metastatic Castration-Resistant Prostate Cancer Patients: Data from Patients in the J-RAP-BSI Trial.
    Kitajima K; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Sasaki R; Narita M; Yamakado K
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of bone scan index change over time on automated calculation in bone scintigraphy.
    Shintawati R; Achmad A; Higuchi T; Shimada H; Hirasawa H; Arisaka Y; Takahashi A; Nakajima T; Tsushima Y
    Ann Nucl Med; 2015 Dec; 29(10):911-20. PubMed ID: 26373556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.